ÂÜÀòÂÒÂ×

Christopher Jamison has a diverse background in the pharmaceutical industry. Christopher began their career at Cytokinetics as a Medicinal Chemistry RA from July 2007 to June 2009. Christopher then joined Bristol Myers Squibb, where they worked as a Process Chemist from March 2017 to September 2019, and later as a Medicinal Chemist from September 2019 to July 2022. Since July 2022, they have been working as a Principal Scientist, Medicinal Chemistry at Loxo Oncology at Lilly.

Christopher Jamison completed their Bachelor's degree in Biochemistry from the University of Nevada, Reno from 2003 to 2007. Christopher then pursued a Doctor of Philosophy (PhD) in Organic Chemistry from Princeton University, which they completed from 2009 to 2014. Following that, they engaged in postdoctoral research in Organic Chemistry at UC Irvine from 2014 to 2017.